Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine
Open Access
- 24 April 2026
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 66 (7) , 1257-1264
Abstract
Background: Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3 , is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design and Methods: We used CRISPR‐Cas9 gene editing to generate an EMP3 knockout (EMP3KO) induced pluripotent stem cell (iPSC) line from a type O, Rh null parent line, enabling production of rare MAM‐negative red blood cells. Since a prior study suggested that loss of EMP3 may enhance erythroid proliferation, we hypothesized that EMP3KO could both yield a rare reagent cell and potentially improve erythroid expansion to support scalable production. Transcriptomic analysis allowed us to further investigate the effect of EMP3 loss in late erythroblasts. Results: EMP3KO cells differentiated efficiently into erythroid cells, showing >95% CD235/CD71 co‐expression and orthochromatic erythroblast morphology. Compared to unedited cells, no proliferative advantage was observed, contrasting with prior non‐isogenic cell models. Agglutination assays confirmed complete loss of MAM antigen and demonstrated the diagnostic utility for identifying MAM antibodies. Transcriptomic profiling of EMP3KO erythroblasts revealed expression of key erythroid genes, as well as regulators of proliferation and heme metabolism, was comparable to the parent line. Discussion: This study demonstrates that iPSC technology combined with gene editing can generate rare antigen‐negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high‐prevalence antigens.Keywords
Funding Information
- National Institutes of Health (U01 HL134696)
- National Institutes of Health (HL169401)
- National Institutes of Health (HL178144)
- National Institutes of Health (T32 HL007150)
- Children's Hospital of Philadelphia
This publication has 19 references indexed in Scilit:
- Generation of red blood cells from induced pluripotent stem cellsCurrent Opinion in Hematology, 2024
- Highly Efficient CRISPR/Cas9‐Mediated Genome Editing in Human Pluripotent Stem CellsCurrent Protocols, 2022
- ABO gene editing for the conversion of blood type A to universal type O in Rhnull donor‐derived human‐induced pluripotent stem cellsClinical and Translational Medicine, 2022
- HDFN Resulting from Anti-U: Alternatives to Allogeneic Intrauterine TransfusionLaboratory Medicine, 2021
- Generation of ‘designer erythroblasts’ lacking one or more blood group systems from CRISPR/Cas9 gene‐edited human‐induced pluripotent stem cellsJournal of Cellular and Molecular Medicine, 2021
- Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteinsNature Communications, 2020
- Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotypeNature Communications, 2020
- Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cellsProceedings of the National Academy of Sciences, 2012
- The global burden of Rh diseaseArchives of Disease in Childhood - Fetal and Neonatal Edition, 2010
- MAM: a “new” high‐incidence antigen found on multiple cell linesTransfusion, 2000